TickerGuard
Buy Day today: Neutral (61) Mixed market breadth · no major macro event
IFRX

InflaRx N.V.

Healthcare · Biotechnology

1.20$ -2.5% vs. previous close Closing price · As of: Nov 11, 2026

Ownership

Ownership Structure

Who owns InflaRx N.V. (IFRX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 66.6% of the shares are freely tradable; institutional investors hold 70.4%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 70.4%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 2.9%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 66.6%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 9.4%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 147Mio.

Largest Shareholders

Institutions

Institutions IFRX
Name Stake (%) Shares Change (%) Date
Suvretta Capital Management, LLC 15.56 22,933,910 +189.1 06/30/2026
TCG Crossover Management, LLC 9.84 14,500,000 +0.0 06/30/2026
FMR Inc 5.54 8,163,341 +0.0 06/30/2026
COMMODORE CAPITAL LP 4.95 7,300,000 +0.0 06/30/2026
Kalehua Capital Management LLC 3.93 5,795,538 +0.0 06/30/2026
Spruce Street Capital LP 3.63 5,352,198 +0.0 06/30/2026
Farallon Capital Management, L.L.C. 2.26 3,325,000 +0.0 06/30/2026
StemPoint Capital LP 2.19 3,228,255 +0.0 06/30/2026

Funds

Funds IFRX
Name Stake (%) Shares Change (%) Date
Fidelity Small Cap Growth 2.23 3,289,530 +0.0 07/31/2026
Fidelity Advisor Biotechnology I 2.17 3,196,071 +0.0 08/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: November 11, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?